#ESMO26 VOLGA（III 期，N=695）：不适合或拒绝顺铂治疗的 MIBC 患者。围手术期 durvalumab 联合新辅助 enfortumab vedotin 与根治性膀胱切除术 ± 辅助治疗：2 年 EFS 64% 对 45%（HR 0.51）；2 年 OS 78% 对 69%（HR 0.58；95% CI：0.40-0.83；p=0.0027）。
6 浏览 · 0 赞 · 0 转发 · 0 回复
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.org来源：Rafał Bogdan Drobot · x.com